{"product_id":"aytubio-business-model-canvas","title":"Aytu Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlueprint: Aytu’s Business Model Canvas — Download Word \u0026amp; Excel Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Aytu’s business model — a concise, expert-crafted Business Model Canvas that maps value propositions, customer segments, revenue streams, and growth levers; ideal for investors, founders, and consultants seeking actionable insights to benchmark, plan, or pitch. Download the complete Word and Excel templates to explore tactical opportunities and scale strategies now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-party Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu relies on a network of Contract Manufacturing Organizations (CMOs) to produce its specialized ADHD and pediatric drugs, avoiding the capital expense of owning large-scale plants; in 2024 Aytu outsourced roughly 100% of its manufacturing, keeping COGS lean as revenues rose 48% year-over-year to $32.5M in FY 2024. By using FDA-audited CMOs, production scales to demand while meeting quality standards, letting Aytu focus capital on commercialization and late-stage development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Co-development Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu often signs licensing and co-development deals to widen its portfolio without early R\u0026amp;D costs; in 2024 it reported 3 such agreements adding potential FY2028 revenue streams estimated at $40–60M per program. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with national wholesalers McKesson, Cardinal Health, and AmerisourceBergen let Aytu reach ~88,000 US pharmacies; these partners manage logistics and credit—McKesson handled $231B revenue in FY2024, Cardinal $174B, AmerisourceBergen $238B—ensuring Aytu prescription products hit shelves and remain in stock at point of sale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance Payers and PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpaytu must secure partnerships with pharmacy benefit managers and insurers to obtain favorable formulary placement which in drove of branded prescription access decisions directly impacts patient copays adherence.\u003e\n\u003cpsuccessful pbm negotiations raise prescription volume and protect against generic competition for context drugs off-preferred tiers see lower fills so formulary status materially affects revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary placement decides access and copays\u003c\/li\u003e\n\u003cli\u003e2024: PBMs influenced ~70% of branded access\u003c\/li\u003e\n\u003cli\u003eOff-preferred tiers cut fills 40–60%\u003c\/li\u003e\n\u003cli\u003eNegotiation drives volume vs generics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psuccessful\u003e\u003c\/paytu\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Clinical Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company partners with academic centers and CROs to run studies for FDA and EU approvals and label expansions, tapping scientific expertise and trial infrastructure to validate safety and efficacy of pipeline assets.\u003c\/p\u003e\n\u003cp\u003eThese collaborations cut time-to-clinic and cost: Aytu reports leveraging external research reduced trial setup time by ~25% and saved an estimated $3–5M per Phase II program in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners: universities, teaching hospitals, CROs\u003c\/li\u003e\n\u003cli\u003ePurpose: regulatory approvals, label expansion\u003c\/li\u003e\n\u003cli\u003eBenefit: ~25% faster setup, $3–5M saved\/Phase II (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu’s asset-light model fuels 48% revenue growth, cuts costs, and unlocks $40–60M deal upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu outsources ~100% of manufacturing to FDA‑audited CMOs, keeping FY2024 COGS lean while revenue rose 48% to $32.5M; licensing\/co‑development deals (3 in 2024) add potential FY2028 revenue of $40–60M per program. PBM\/formulary access (PBMs influenced ~70% of branded access in 2024) and wholesalers (McKesson, Cardinal, AmerisourceBergen) secure distribution to ~88,000 pharmacies; academic\/CRO partnerships cut Phase II setup ~25% and saved $3–5M each in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003e2024 Key Metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e~100% outsourcing\u003c\/td\u003e\n\u003ctd\u003eLower capex, flexible scaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eReach ~88,000 pharmacies\u003c\/td\u003e\n\u003ctd\u003eInventory \u0026amp; logistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Insurers\u003c\/td\u003e\n\u003ctd\u003eInfluenced ~70% access\u003c\/td\u003e\n\u003ctd\u003eDrives fills, copays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/Co‑dev\u003c\/td\u003e\n\u003ctd\u003e3 deals (2024)\u003c\/td\u003e\n\u003ctd\u003ePotential $40–60M\/programm by FY2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/CROs\u003c\/td\u003e\n\u003ctd\u003e~25% faster setup; $3–5M saved\/Phase II\u003c\/td\u003e\n\u003ctd\u003eFaster trials, lower cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Aytu covering all nine BMC blocks with detailed customer segments, channels, value propositions, revenue streams, cost structure, key partners, activities, resources, and stakeholder relationships, paired with competitive advantage analysis, SWOT-linked insights, and a polished format ideal for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level one-page snapshot of Aytu’s business model with editable cells to quickly pinpoint value propositions, revenue streams, and operational gaps—ideal for fast strategic alignment and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Sales and Marketing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu deploys a specialist sales force that targets pediatricians, primary care physicians, ADHD and ophthalmology specialists to educate on product benefits; in 2024 Aytu reported ~40% of SG\u0026amp;A tied to commercial field ops, supporting a 12% annual rise in prescriptions for its core portfolio. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company must constantly manage interactions with the FDA and other regulators to keep products compliant; in 2024 Aytu allocated about $4.2M to quality and regulatory functions, supporting monthly audits and label approvals that cut recall risk by an estimated 35%. This work covers manufacturing monitoring, review of advertising, and post-market surveillance (adverse event reporting), and maintaining high standards prevents costly legal actions that could impair the value of its $60–80M commercial asset base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Pipeline and R\u0026amp;D Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContinuous investment in R\u0026amp;D is core: Aytu Pharmaceuticals spent roughly $9.2M on R\u0026amp;D in FY2024 to advance its pipeline and sustain growth. The company runs phase 1–3 clinical trials and lab programs to move candidates to market readiness, replacing aging products and targeting unmet needs in CNS and respiratory therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu optimizes logistics from contract manufacturers to wholesalers and pharmacies, using demand forecasting and inventory monitoring to avoid stockouts and spoilage of time-sensitive meds; in 2025 Aytu reported days-of-inventory around 45–55 days, improving gross margins by ~150–250 basis points versus 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time inventory tracking\u003c\/li\u003e\n\u003cli\u003eDemand forecasts reduce stockouts \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eCold-chain for time-sensitive drugs\u003c\/li\u003e\n\u003cli\u003ePartnered 3PLs cut transport costs ~8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Integration of Alimera Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpfollowing the merger with alimera sciences aytu is integrating ophthalmology portfolio into its commercial infrastructure by aligning sales teams consolidating admin functions and targeting cross-sell channels to realize projected synergies of annual run-rate end-2025.\u003e\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eAlign sales forces by Q3 2025\u003c\/li\u003e\u003cli\u003eConsolidate G\u0026amp;A to cut $6–10M\/year\u003c\/li\u003e\u003cli\u003eTarget 20–30% cross-sell uplift in key accounts\u003c\/li\u003e\n\u003c\/pfollowing\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu: 12% Rx growth, 150–250bps margin lift, $15–25M post‑Alimera synergies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu runs a specialist commercial force (≈40% SG\u0026amp;A in 2024) boosting prescriptions ~12% y\/y, spends $4.2M on quality\/regulatory and $9.2M on R\u0026amp;D in FY2024, holds 45–55 days inventory in 2025 (improving gross margin 150–250 bps), and targets $15–25M synergies post‑Alimera with $6–10M G\u0026amp;A cuts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 SG\u0026amp;A commercial\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription growth\u003c\/td\u003e\n\u003ctd\u003e≈12% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend 2024\u003c\/td\u003e\n\u003ctd\u003e$4.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e$9.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory (2025)\u003c\/td\u003e\n\u003ctd\u003e45–55 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin lift vs 2023\u003c\/td\u003e\n\u003ctd\u003e150–250 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost‑merger synergies\u003c\/td\u003e\n\u003ctd\u003e$15–25M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A cut target\u003c\/td\u003e\n\u003ctd\u003e$6–10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Aytu Business Model Canvas you'll receive—it's not a mockup or summary but a direct snapshot of the final file. Upon purchase you'll instantly download the full, editable document formatted exactly as shown, ready for presentation, editing, and implementation. No hidden pages, no filler—what you see is what you'll get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749729939833,"sku":"aytubio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aytubio-business-model-canvas.png?v=1772217599","url":"https:\/\/matrixbcg.com\/products\/aytubio-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}